Cargando…

Clinical Efficacy and Adverse Reactions of Bevacizumab plus Radiochemotherapy in the Treatment of Advanced Gastric Cancer

OBJECTIVE: To evaluate the clinical efficacy and adverse reactions of bevacizumab plus radiochemotherapy in the treatment of advanced gastric cancer. METHODS: Eighty-six eligible patients with gastric cancer treated in our institution from August 2019 to August 2020 were recruited and concurrently r...

Descripción completa

Detalles Bibliográficos
Autor principal:	Wei, Fang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847024/ https://www.ncbi.nlm.nih.gov/pubmed/35178088 http://dx.doi.org/10.1155/2022/4900037

Ejemplares similares

Preoperative treatment with radiochemotherapy for locally advanced gastroesophageal junction cancer and unresectable locally advanced gastric cancer
por: Ratosa, Ivica, et al.
Publicado: (2015)

Induction chemotherapy with albumin-bound paclitaxel plus lobaplatin followed by concurrent radiochemotherapy for locally advanced esophageal cancer
por: Yan, Mao-Hui, et al.
Publicado: (2021)

Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer
por: Dellas, Kathrin, et al.
Publicado: (2013)

Clinical Efficacy and Safety of Bevacizumab, Apatinib, and Recombinant Human Endothelial Inhibitor in the Treatment of Advanced Gastric Cancer
por: Wang, Liang, et al.
Publicado: (2022)

Concurrent radiochemotherapy in advanced hypopharyngeal cancer
por: Krstevska, Valentina, et al.
Publicado: (2010)

Efficacy of Bevacizumab and Gemcitabine in Combination with Cisplatin in the Treatment of Esophageal Cancer and the Effect on the Incidence of Adverse Reactions
por: Wang, Jiangfeng, et al.
Publicado: (2022)

Clinical study of nimotuzumab combined with concurrent radiochemotherapy for treatment of locally advanced cervical cancer
por: Chen, Wenli, et al.
Publicado: (2019)

Capecitabine in adjuvant radiochemotherapy for gastric adenocarcinoma
por: Oblak, Irena, et al.
Publicado: (2014)

Evaluation of Efficacy and Tolerance of Radical Radiotherapy and Radiochemotherapy in Treatment of Locally Advanced, Unresectable Rectal Cancer
por: Kraszkiewicz, M., et al.
Publicado: (2022)

Tumor Microenvironment Status Predicts the Efficacy of Postoperative Chemotherapy or Radiochemotherapy in Resected Gastric Cancer
por: Duan, Ran, et al.
Publicado: (2021)

Triapine Radiochemotherapy in Advanced Stage Cervical Cancer
por: Kunos, Charles A., et al.
Publicado: (2018)

Adjuvant radiochemotherapy in locally advanced gastric cancer: from evidence to daily clinical practice in a single institution
por: González-Domingo, Manuel, et al.
Publicado: (2020)

A case report of vesicovaginal fistula following Bevacizumab without pelvic disease and radiochemotherapy
por: Zhang, Junlong, et al.
Publicado: (2022)

Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China
por: Gong, Hongyu, et al.
Publicado: (2023)

Efficacy and safety of Kanglaite injection combined with radiochemotherapy in the treatment of advanced pancreatic cancer: A PRISMA-compliant meta-analysis
por: Liu, Jianling, et al.
Publicado: (2019)

Radiochemotherapy
Publicado: (1998)

Adjuvant Radiochemotherapy versus Chemotherapy Alone for Gastric Cancer: Implications for Target Definition
por: Xu, Jing, et al.
Publicado: (2019)

microRNAs expression profile related with response to preoperative radiochemotherapy in patients with locally advanced gastric cancer
por: Liu, Xiaowen, et al.
Publicado: (2018)

A case report of endorectal displacement of a right ureteral stent following radiochemotherapy and Bevacizumab
por: Tognarelli, Alessio, et al.
Publicado: (2019)

Real-world efficacy and safety of bevacizumab single-maintenance therapy following platinum-paclitaxel chemotherapy plus bevacizumab in patients with advanced cervical cancer
por: Kotaka, Saki, et al.
Publicado: (2023)

Influence of Gender on Radiosensitivity during Radiochemotherapy of Advanced Rectal Cancer
por: Schuster, Barbara, et al.
Publicado: (2021)

Adverse Event with the Use of Carmustine Wafers and Postoperative Radiochemotherapy for the Treatment of High-grade Glioma
por: Salle, Federico, et al.
Publicado: (2018)

Efficacy of XELOX plus Bevacizumab in Brain Metastasis from Rectal Cancer
por: Yoshida, Yoichiro, et al.
Publicado: (2014)

The efficacy and adverse reactions of DCF and FOLFOXs regimens for patients with advanced gastric cancer in China: a meta-analysis
por: Chen, Minxue, et al.
Publicado: (2020)

Clinical efficacy and safety of atezolizumab plus bevacizumab versus lenvatinib in the treatment of advanced hepatocellular carcinoma: A systematic review and meta-analysis
por: Du, Sihao, et al.
Publicado: (2023)

Neoadjuvant Bevacizumab Plus Docetaxel/Cisplatin/Capecitabine Chemotherapy in Locally Advanced Gastric Cancer Patients: A Pilot Study
por: Yu, Deguo, et al.
Publicado: (2022)

Bevacizumab plus cisplatin and helical tomotherapy in treatment of locally advanced nasopharyngeal carcinoma
por: Li, Jianxiong, et al.
Publicado: (2015)

FOLFOXIRI plus bevacizumab as standard of care for first-line treatment in patients with advanced colon cancer
por: Cervantes, A., et al.
Publicado: (2023)

Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma
por: Hsu, C-H, et al.
Publicado: (2010)

Evaluation of clinical efficacy, adverse reactions, and safety of PD-1 inhibitors combined with chemotherapy when treating advanced gastric cancer
por: Huang, Xue, et al.
Publicado: (2023)

Radiochemotherapy-induced DNA repair promotes the biogenesis of gastric cancer stem cells
por: Lu, Yu, et al.
Publicado: (2022)

Neoadjuvant Therapy of DOF Regimen Plus Bevacizumab Can Increase Surgical Resection Ratein Locally Advanced Gastric Cancer: A Randomized, Controlled Study
por: Ma, Junxun, et al.
Publicado: (2015)

Clinical Efficacy, Survival, and Adverse Reaction Evaluation of Immune Checkpoint Inhibitor in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis
por: Zhang, Ping, et al.
Publicado: (2022)

Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma
por: Xin, Yujing, et al.
Publicado: (2022)

Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab
por: Hsu, Chiun, et al.
Publicado: (2021)

Baseline neutrophil-to-lymphocyte ratio and c-reactive protein predict efficacy of treatment with bevacizumab plus paclitaxel for locally advanced or metastatic breast cancer
por: Miyagawa, Yoshimasa, et al.
Publicado: (2020)

Efficacy and safety of atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma in the real world: a single-arm meta-analysis
por: Gao, Xiaoqiang, et al.
Publicado: (2023)

Lymphopaenia and accidental splenic doses: Do they have any prognostic value for locally advanced gastric cancer patients treated with radiochemotherapy?
por: Sert, Fatma, et al.
Publicado: (2019)

Neoadjuvant versus definitive radiochemotherapy of locoregionally advanced oesophageal cancer—who benefits?
por: Schiffner, Christoph, et al.
Publicado: (2022)

Prognostic value of sarcopenia in patients treated by Radiochemotherapy for locally advanced oesophageal cancer
por: Mallet, Romain, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9mcblk0d6us2imbbv7cjmsj0ji